

WHAT IS CLAIMED IS:

1. A therapeutic agent for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient.
2. The agent of claim 1 wherein the cartilage growth inhibition is rescued by enlarging hypertrophic chondrocytes and increasing the extracellular matrix of the proliferative chondrocyte layer.
3. The agent of claim 1 or 2 wherein the substance activating GC-B is a peptide.
4. The agent of claim 3 wherein the peptide is a C-type natriuretic peptide (CNP).
5. The agent of claim 4 wherein the CNP is CNP-22 or CNP-53.